Low ERRC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2286-2291

  Lord, Reginald V N ^a   Brabender, Jan ^a   Gandara, David ^b   Alberola, Vicente ^c   Camps, Carlos ^d   Domine, Manuel ^e   Cardenal, Felip ^f   Sánchez, José M ^g   Gumerlock, Paul H ^b   Tarón, Miquel ^g   Sánchez, José J ^h   Danenberg, Kathleen D ⁱ   Danenberg, Peter V ^a   Rosell, Rafael ^g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e Fundación Jiménez Díaz   (Spain)

^f CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h University Hospital of Madrid   (Spain)

ⁱ Response Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; GEMCITABINE; MESSENGER RNA; PROTEIN; IFOSFAMIDE; NAVELBINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT OUTCOME; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; EXCISION REPAIR; GENE EXPRESSION; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035988959     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
2. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
3. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
4. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-acetoammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts
5. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells
6. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene
7. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: Association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins
8. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy
9. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy
10. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
11. Synergistic interaction between cisplatin and gemcitabine in vitro
12. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer
13. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines
14. Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
15. Expression of ERCC1 antisense RNA abrogates Gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair
16. Cisplatin/Gemcitabine (CG) versus cisplatin/Gemcitabine/vinorelbine (CGV) versus sequential doublets of Gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced NSCLC: Results of a Spanish Lung Cancer Group Phase III trial (GEPC/98-02)
17. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence
18. A novel method for real time quantitative RT-PCR
19. Real time quantitative PCR
20. 2 statistics
21. 2 statistics for small samples
22. Molecular cloning of a human DNA repair gene
23. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination
24. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3
25. DNA repair: Enzymatic mechanisms and relevance to drug response
26. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients
27. Low thymidylate synthase and ERCC1 gene expressions are associated with increased survival after neoadjuvant 5-FU/cisplatin/radiotherapy for esophageal adenocarcinoma
28. Quantitative ERCC1 RNA expression identifies non-response to cis-platinum based neoadjuvant radiochemotherapy for esophageal cancer
29. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
30. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
31. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized Phase III study of the Italian Lung Cancer Project
32. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
33. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial
34. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A Phase III multicentre randomised trial
35. A randomized trial with mitomycin-C/ ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer
36. A randomized Phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non small cell lung cancer (NSCLC). A preliminary analysis
37. Randomized Phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC): A West Japan Thoracic Oncology Group (WJTOG) study
38. A EORTC randomized Phase III trial of three chemotherapy regimens in advanced non-small-cell lung cancer (NSCLC)
39. Predictive molecular markers in non-small cell lung cancer
40. Advances in the treatment of non-small cell lung cancer: Molecular markers take the stage
41. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels
42. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma
43. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations
44. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor